High quality Docetaxel intermediate Cas 114915-14-9 with best price and fast delivery

Details:

Docetaxel Intermediate: An Overview

1. Definition and Context
Docetaxel is a semi-synthetic chemotherapeutic agent belonging to the taxane class, used to treat cancers such as breast, prostate, and non-small cell lung cancer. An intermediate in its synthesis refers to a compound formed during the multi-step production process before the final active pharmaceutical ingredient (API) is obtained. These intermediates are critical for efficient and scalable manufacturing.

2. Key Intermediates in Docetaxel Synthesis

Docetaxel is derived from natural precursors through semi-synthetic modification. Below are the pivotal intermediates in its production:

(a) 10-Deacetylbaccatin III (10-DAB III)

Source: Extracted from the needles of Taxus (yew) species.

Role: The foundational scaffold for synthesis. It lacks the C-10 acetyl group and the C-13 side chain present in docetaxel.

• Modifications:

  • C-10 Hydroxyl Protection: The hydroxyl group at C-10 is acetylated to prevent unwanted reactions.

  • C-13 Side Chain Addition: A synthetic side chain is attached to this position to confer bioactivity.

(b) Protected 10-Deacetylbaccatin III Derivatives

Example: 7-Triethylsilyl-10-deacetylbaccatin III (introduces a protecting group at C-7).

Purpose: Protecting groups (e.g., triethylsilyl, acetyl) shield reactive hydroxyl groups during subsequent reactions.

(c) Side Chain Intermediates

Structure: The docetaxel side chain is N-tert-butoxycarbonyl (Boc)-protected phenylisoserine.

Role: This side chain is chemically synthesized and coupled to the C-13 position of the modified baccatin III core.

Coupling Reaction: Achieved via esterification or other coupling reagents (e.g., dicyclohexylcarbodiimide, DCC).

(d) Deprotected Intermediate

Process: After coupling, protecting groups (e.g., silyl, Boc) are removed under controlled conditions (e.g., acidic hydrolysis).

Outcome: Yields the final docetaxel structure with free hydroxyl groups and the active side chain.

3. Significance of Intermediates

Scalability: Semi-synthetic routes reduce reliance on scarce natural sources (e.g., yew bark for paclitaxel).

Quality Control: Intermediates allow precise monitoring and optimization of synthesis steps.

Cost-Effectiveness: Efficient intermediates streamline production, critical for high-value drugs like docetaxel.

4. Challenges in Synthesis

Structural Complexity: The tetracyclic diterpene core and stereochemistry demand precise reaction conditions.

Protection/Deprotection Steps: Multiple steps increase synthesis time and risk of side reactions.

Regulatory Compliance: Intermediates must meet strict purity standards for pharmaceutical use.

5. Conclusion

Docetaxel intermediates like 10-DAB III, protected derivatives, and synthetic side chains are essential for its semi-synthetic production. These compounds enable scalable, cost-effective manufacturing while maintaining the structural integrity required for antitumor activity. Advances in synthetic chemistry continue to optimize these pathways, ensuring reliable access to this life-saving drug.